Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 1/20 | 0.44 |
| ▸ | METAP2 | P50579 | 4/20 | 0.42 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | CCR9 | P51686 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | EDNRA | P25101 | 4/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | FABP4 | P15090 | 1/20 | 0.36 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | SLC10A6 | Q3KNW5 | 1/20 | 0.35 |
| ▸ | EDNRB | P24530 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2748820 | 0.90 | KCNH2 (0.53) | METAP2PARP14KCNH2CCR9MEN1 | |
| SCHEMBL2748298 | 0.86 | ACLY (0.48) | ACLYPARP14KCNH2KDM4ECCR9 | |
| SCHEMBL2747267 | 0.84 | ACLY (0.54) | ACLYPARP14KCNH2KDM4ECCR9 | |
| SCHEMBL2747699 | 0.83 | ACLY (0.45) | ACLYPARP14KCNH2KDM4ECCR9 | |
| SCHEMBL2747034 | 0.83 | ACLY (0.45) | ACLYPARP14KCNH2KDM4ECCR9 | |
| SCHEMBL2748800 | 0.81 | KCNH2 (0.48) | ACLYPARP14KCNH2KDM4ECCR9 | |
| SCHEMBL2747619 | 0.81 | ACLY (0.51) | ACLYPARP14KCNH2KDM4ECCR9 | |
| SCHEMBL2747643 | 0.81 | ACLY (0.53) | ACLYPARP14KCNH2KDM4ECCR9 | |
| SCHEMBL2747872 | 0.80 | ACLY (0.52) | ACLYPARP14KCNH2KDM4ECCR9 | |
| SCHEMBL2748580 | 0.79 | ACLY (0.57) | ACLYPARP14KCNH2KDM4ECCR9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178699-B2 | Modulators of CCR9 receptor and methods of use thereof | PFIZER INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-8178699-B2 | Modulators of CCR9 receptor and methods of use thereof | PFIZER INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-8178699-B2 | Modulators of CCR9 receptor and methods of use thereof | PFIZER INC. (US) | 2012-05-15 | — | — | US | disclosed |
| EP-2220065-A2 | MODULATORS OF CCR9 RECEPTOR AND METHODS OF USE THEREOF | ENCYSIVE PHARMACEUTICALS, INC. (US) | 2010-08-25 | — | — | EP | disclosed |
| US-20100029753-A1 | MODULATORS OF CCR9 RECEPTOR AND METHODS OF USE THEREOF | ENCYSIVE PHARMACEUTICALS, INC. | 2010-02-04 | — | — | US | disclosed |
| US-20100029753-A1 | MODULATORS OF CCR9 RECEPTOR AND METHODS OF USE THEREOF | ENCYSIVE PHARMACEUTICALS, INC. | 2010-02-04 | — | — | US | disclosed |
| US-20100029753-A1 | MODULATORS OF CCR9 RECEPTOR AND METHODS OF USE THEREOF | ENCYSIVE PHARMACEUTICALS, INC. | 2010-02-04 | — | — | US | disclosed |
| WO-2009017719-A2 | MODULATORS OF CCR9 RECEPTOR AND METHODS OF USE THEREOF | ENCYSIVE PHARMACEUTICALS, INC. (US) | 2009-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029753-A1 | MODULATORS OF CCR9 RECEPTOR AND METHODS OF USE THEREOF | CCR9, CCR1, CCR4 | ACLY 4546/4885METAP2 1177/4885PARP14 2997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.